GOLM1 depletion modifies cellular sphingolipid metabolism and adversely affects cell growth.


Journal

Journal of lipid research
ISSN: 1539-7262
Titre abrégé: J Lipid Res
Pays: United States
ID NLM: 0376606

Informations de publication

Date de publication:
09 2022
Historique:
received: 12 04 2022
revised: 11 07 2022
accepted: 12 07 2022
pubmed: 11 8 2022
medline: 5 10 2022
entrez: 10 8 2022
Statut: ppublish

Résumé

Golgi membrane protein 1 (GOLM1) is a Golgi-resident type 2 transmembrane protein known to be overexpressed in several cancers, including hepatocellular carcinoma (HCC), as well as in viral infections. However, the role of GOLM1 in lipid metabolism remains enigmatic. In this study, we employed siRNA-mediated GOLM1 depletion in Huh-7 HCC cells to study the role of GOLM1 in lipid metabolism. Mass spectrometric lipidomic analysis in GOLM1 knockdown cells showed an aberrant accumulation of sphingolipids, such as ceramides, hexosylceramides, dihexosylceramides, sphinganine, sphingosine, and ceramide phosphate, along with cholesteryl esters. Furthermore, we observed a reduction in phosphatidylethanolamines and lysophosphatidylethanolamines. In addition, Seahorse extracellular flux analysis indicated a reduction in mitochondrial oxygen consumption rate upon GOLM1 depletion. Finally, alterations in Golgi structure and distribution were observed both by electron microscopy imaging and immunofluorescence microscopy analysis. Importantly, we found that GOLM1 depletion also affected cell proliferation and cell cycle progression in Huh-7 HCC cells. The Golgi structural defects induced by GOLM1 reduction might potentially affect the trafficking of proteins and lipids leading to distorted intracellular lipid homeostasis, which may result in organelle dysfunction and altered cell growth. In conclusion, we demonstrate that GOLM1 depletion affects sphingolipid metabolism, mitochondrial function, Golgi structure, and proliferation of HCC cells.

Identifiants

pubmed: 35948172
pii: S0022-2275(22)00092-X
doi: 10.1016/j.jlr.2022.100259
pmc: PMC9475319
pii:
doi:

Substances chimiques

Ceramides 0
Cholesterol Esters 0
GOLM1 protein, human 0
Membrane Proteins 0
Phosphates 0
Phosphatidylethanolamines 0
RNA, Small Interfering 0
Sphingolipids 0
Sphingosine NGZ37HRE42

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100259

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Meghana Nagaraj (M)

Minerva Foundation Institute for Medical Research, Biomedicum, Helsinki, Finland; Doctoral Programme in Integrative Life Science, University of Helsinki, Helsinki, Finland.

Marcus Höring (M)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.

Maria A Ahonen (MA)

Minerva Foundation Institute for Medical Research, Biomedicum, Helsinki, Finland; Doctoral Programme in Clinical Research, University of Helsinki, Helsinki, Finland.

Van Dien Nguyen (VD)

Systems Immunity University Research Institute, and Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom.

You Zhou (Y)

Systems Immunity University Research Institute, and Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom.

Helena Vihinen (H)

Electron Microscopy Unit, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Eija Jokitalo (E)

Electron Microscopy Unit, Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Gerhard Liebisch (G)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.

P A Nidhina Haridas (PA)

Minerva Foundation Institute for Medical Research, Biomedicum, Helsinki, Finland. Electronic address: nidhina.haridas@helsinki.fi.

Vesa M Olkkonen (VM)

Minerva Foundation Institute for Medical Research, Biomedicum, Helsinki, Finland; Department of Anatomy, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Electronic address: vesa.olkkonen@helsinki.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH